Literature DB >> 19153873

Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome.

Margot G F Van Lier1, Johannes H W De Wilt, Jessie J M F Wagemakers, Winand N M Dinjens, Ronald A M Damhuis, Anja Wagner, Ernst J Kuipers, Monique E Van Leerdam.   

Abstract

OBJECTIVE: The revised Bethesda Guidelines were published to improve the efficiency of recognizing Lynch syndrome (LS) by identifying LS-related malignancies that should be analyzed for microsatellite instability (MSI). The aim of this study was to evaluate whether MSI analysis was performed in colorectal cancer patients at risk for LS according to the revised Bethesda Guidelines.
MATERIAL AND METHODS: Patients diagnosed with colorectal cancer in 11 Dutch hospitals in 2005 and 2006 were selected from a regional database. The patients were included in the study if they met any of the following criteria; 1) diagnosed with colorectal cancer <50 years, 2) a second LS-associated tumor prior to the diagnosis of colorectal cancer in 2005/2006, and 3) colorectal cancer <60 years with a tumor displaying mucinous or signet-ring differentiation or medullary growth pattern.
RESULTS: Of 1905 colorectal cancer patients, 169 met at least one of the inclusion criteria. MSI analysis had been performed in 23 (14%) of the 169 tumors. MSI status had been determined in 18 of 80 included patients aged <50 years, in 4 of 70 patients with a second LS-related tumor, and in 3 of 41 patients aged <60 years with high-risk pathology features.
CONCLUSIONS: There is marked underutilization of MSI analysis in patients at risk for LS. As a result LS might be underdiagnosed both in patients with colorectal cancer and in their relatives.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153873     DOI: 10.1080/00365520802706008

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  14 in total

1.  Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer.

Authors:  Paul G van Putten; Margot G F van Lier; Mariska Hage; Katharina Biermann; Reinier H van Rijssel; Pieter J Westenend; Hans Morreau; Ewout W Steyerberg; Winand N M Dinjens; Ernst J Kuipers; Monique E van Leerdam; J Han van Krieken
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

2.  Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives.

Authors:  Jessica Ezzell Hunter; Kathleen A Arnold; Jennifer E Cook; Jamilyn Zepp; Marian J Gilmore; Alan F Rope; James V Davis; Kellene M Bergen; Elizabeth Esterberg; Kristin R Muessig; Susan K Peterson; Sapna Syngal; Louise Acheson; Georgia Wiesner; Jacob Reiss; Katrina A B Goddard
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

3.  Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting.

Authors:  Elizabeth V Clarke; Kristin R Muessig; Jamilyn Zepp; Jessica E Hunter; Sapna Syngal; Louise S Acheson; Georgia L Wiesner; Susan K Peterson; Kellene M Bergen; Elizabeth Shuster; James V Davis; Jennifer L Schneider; Tia L Kauffman; Marian J Gilmore; Jacob A Reiss; Alan F Rope; Jennifer E Cook; Katrina A B Goddard
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

4.  Population-Based Lynch Syndrome Screening by Microsatellite Instability in Patients ≤50: Prevalence, Testing Determinants, and Result Availability Prior to Colon Surgery.

Authors:  Jordan J Karlitz; Mei-Chin Hsieh; Yong Liu; Christine Blanton; Beth Schmidt; J Milburn Jessup; Xiao-Cheng Wu; Vivien W Chen
Journal:  Am J Gastroenterol       Date:  2015-01-20       Impact factor: 10.864

5.  Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center.

Authors:  Brandie Heald; Thomas Plesec; Xiuli Liu; Rish Pai; Deepa Patil; Jessica Moline; Richard R Sharp; Carol A Burke; Matthew F Kalady; James Church; Charis Eng
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

6.  Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults.

Authors:  Talha Shaikh; Elizabeth A Handorf; Joshua E Meyer; Michael J Hall; Nestor F Esnaola
Journal:  JAMA Oncol       Date:  2018-02-08       Impact factor: 31.777

7.  Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers.

Authors:  Jessica Ezzell Hunter; Jamilyn M Zepp; Mari J Gilmore; James V Davis; Elizabeth J Esterberg; Kristin R Muessig; Susan K Peterson; Sapna Syngal; Louise S Acheson; Georgia L Wiesner; Jacob A Reiss; Katrina A B Goddard
Journal:  Cancer       Date:  2015-06-02       Impact factor: 6.860

8.  Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.

Authors:  Celine H M Leenen; Anne Goverde; Esther W de Bekker-Grob; Anja Wagner; Margot G F van Lier; Manon C W Spaander; Marco J Bruno; Carli M Tops; Ans M W van den Ouweland; Hendrikus J Dubbink; Ernst J Kuipers; Winand N M Dinjens; Monique E van Leerdam; Ewout W Steyerberg
Journal:  Genet Med       Date:  2016-03-03       Impact factor: 8.822

9.  Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer.

Authors:  Deanna S Cross; Alanna Kulchak Rahm; Tia L Kauffman; Jennifer Webster; Anh Quynh Le; Heather Spencer Feigelson; Gwen Alexander; Paul Meier; Adedayo A Onitilo; Pamala A Pawloski; Andrew E Williams; Stacey Honda; Yeehwa Daida; Catherine A McCarty; Katrina A B Goddard
Journal:  Genet Med       Date:  2013-05-02       Impact factor: 8.822

Review 10.  A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.

Authors:  Margot G F van Lier; Anja Wagner; Monique E van Leerdam; Katharina Biermann; Ernst J Kuipers; Ewout W Steyerberg; Hendrikus Jan Dubbink; Winand N M Dinjens
Journal:  J Cell Mol Med       Date:  2009-11-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.